# **RESEARCH ARTICLE**

# Hepatoprotective and body weight lowering effects of the aqueous leaf extract of *Phyllanthus pentandrus* Schumach. and Thonn (*Phyllanthaceae*) in nonalcoholic fatty liver disease induced by a high-fat diet in Wistar rats

# Aminu Chika, Shaibu Oricha Bello

Department of Pharmacology and Therapeutics, College of Health Sciences, Usmanu Danfodiyo University, Sokoto, Nigeria

Correspondence to: Aminu Chika, E-mail: chika.aminu@udusok.edu.ng

Received: September 23, 2019; Accepted: October 18, 2019

# ABSTRACT

**Background:** Some members of the genus *Phyllanthus* have been widely used in global traditional medicine to manage a variety of liver diseases and experimentally documented to have hepatoprotective activity. However, it is not known whether *Phyllanthus pentandrus* (PP) (a member of the genus endogenous to Northwestern Nigeria) possesses hepatoprotective properties. **Aims and Objective:** The objective was to investigate the hepatoprotective and body weight lowering effects of the aqueous leaf extract of PP using a high-fat diet (HFD)-induced rat model of nonalcoholic fatty liver disease (NAFLD). **Materials and Methods:** After obtaining ethical permission from a departmental committee, Wistar rats were randomly assigned to one of the following treatments for 7 weeks: vehicle + normal diet, vehicle + HFD, orlistat + HFD (at 400 mg/1000 g of HFD), or the PP extract +HFD (500 mg/100 g of HFD). Serum levels of liver enzymes (alkaline phosphatase [ALP], aspartate transaminase [AST], and alanine transaminase), conjugated and total bilirubin were determined. Determination of final body weight gain, adipose tissue weight, liver weight, as well as liver histology, was also performed on the animals. **Results:** Compared with normal controls, HFD-fed rats exhibited a significant elevation in ALP, severe liver steatosis, body weight gain, and increased adipose tissue mass. Treatment with the PP extract prevented the increase in the level of ALP, reduced the serum level of AST and ameliorated the hepatic steatosis, and adipose tissue gain. **Conclusion:** These findings suggest that PP may be beneficial in the management of NAFLD commonly associated with obesity.

KEY WORDS: Phyllanthus pentandrus; Fatty Liver; High-Fat Diet; Rats

# INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD), a common comorbid condition associated with obesity, is one of the most common liver disorders worldwide.<sup>[1]</sup> It progresses

Access this article online				
Website: www.njppp.com	Quick Response code			
DOI: 10.5455/njppp.2019.9.1033818102019				

from benign and reversible fatty infiltration to subsequent more serious liver fibrosis. It is categorized into two subtypes: (1) Simple steatosis or steatosis with nonspecific abnormal features and (2) non-alcoholic steatohepatitis, a subtype associated with a higher risk of progression to hepatic fibrosis or cirrhosis. It seems that the mobilization of visceral fat, resulting in the release of free fatty acids into the portal circulation is the primary factor responsible for the liver dysfunction.<sup>[2]</sup> This effect primarily driven by insulin resistance represents the first hit according to the twohit theory for the pathogenesis of NAFLD, with the second hit being the peroxidation of the fatty acids due to various factors producing oxidative stress.<sup>[3,4]</sup>

National Journal of Physiology, Pharmacy and Pharmacology Online 2019. © 2019 Aminu Chika and Shaibu Oricha Bello. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creative commons.org/licenses/by/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for any purpose, even commercially, provided the original work is properly cited and states its license.

Ethnicity, metabolic diseases (type 2 diabetes mellitus and polycystic ovarian syndrome), obesity, chronic infections (HIV, hepatitis C virus), primary aldosteronism, and myotonic dystrophy are some of the risk factors associated with NAFLD.<sup>[5]</sup>

*Phyllanthus pentandrus* (PP) (family: *Phyllanthaceae* and *Genus*: *Phyllanthus*) is an annual or perennial erect or decumbent plant, which is widely distributed in African countries. It is known as "geron tsuntsaye" in Hausa language. Members of the genus *Phyllanthus* are traditionally employed in the management of disease conditions related to NAFLD. For example, *Phyllanthus amarus* is used in the management of obesity<sup>[6]</sup> and liver disorders.<sup>[7]</sup> Previous studies have reported the hepatoprotective and body weight-lowering effects of extracts from some members of the genus *Phyllanthus*.<sup>[8-11]</sup> However, to the best of our knowledge, no previous study has investigated the hepatoprotective or weight-reducing properties of PP.

This study is aimed at evaluating aqueous leaf extract of PP for potential hepatoprotective activity in a high-fat diet (HFD)-fed rat model of NAFLD and investigating the weight-reducing properties of the extract.

# MATERIALS AND METHODS

# **Plant Identification**

The plant selected was identified by Prof A.A. Aliero of Botany unit, Department of Biological Sciences, Faculty of Science, Usmanu Danfodiyo University, Sokoto. The voucher specimen (V/N/PCG/UDUS/EUP/0010) was kept at the herbarium of the Faculty of Pharmaceutical Sciences, Usmanu Danfodiyo University, Sokoto.

# **Test Drugs and Chemicals**

Orlistat (Xenical, Roche Ltd., Switzerland), was purchased from reputable pharmaceutical stores. Kits for alkaline phosphatase (ALP), aspartate transaminase (AST), alanine transaminase (ALT), and total and conjugated bilirubin were purchased from Randox Laboratories (UK). Other chemicals used were of analytical grade.

# Animals

# Wistar rats

Thirty male Wistar rats weighing 180–230 g were used for the study. They were acclimatized for 1 week on a HFD before starting the experiment and were given free access to water. Before the start of the experiment, ethical permission was obtained from a departmental committee, Department of Pharmacology and Therapeutics, College of Health Sciences, Usmanu Danfodiyo University, Sokoto.

# **Formulation of HFD**

The HFD was formulated according to the method of Yang *et al.* (2007).<sup>[12]</sup> Forty grams of sheep tallow (animal fat around the kidneys and loins), 20 g of whole milk, 4 g of sugar, and 36 g of standard formula feed were mixed, giving 100 g of HFD. Based on the baseline average daily feed intake of the animals (100 g of feed/kg bwt of animals), 500 mg of the aqueous leaf extract of PP was incorporated into the HFD. The feeds were stored in a deep freezer to avoid putrefaction until time for use.

# **Plant Preparation and Extraction**

The leaves of the plant were air-dried to constant weight, ground into a fine powder before subjecting them to aqueous extraction (40 g of the dried leaves in 200 ml of water) using plain bottled water. Frequent stirring for 30 min and then rapid filtration through a clean cloth followed this. The marc was squeezed to obtain a combined filtrate.

Ten milliliters aliquot of the combined filtrate was evaporated to estimate the stock concentration, which was stored in a freezer and can be further diluted to required concentration when needed.

Qualitative phytochemical analysis<sup>[13]</sup> was conducted on water extract of the plant for alkaloids, saponins, tannins, flavonoids, cardiac glycosides, anthraquinones, and phytosterols.

# **Design of the Study**

Twenty four rats were randomized into 4 groups (*n*=6 for each group):

Group 1: Negative control on standard low-fat chow

- Group 2: Negative control on the HFD
- Group 3: Positive control treated with orlistat incorporated into a HFD (at 0.04 g%)
- Groups 4: Treated with the extract incorporated into HFD (at 0.5 g%).

The parameters evaluated include baseline and final body weight (after 7 weeks of treatment). Others are weights (in g/100 body weight) of the liver, white (perirenal and epididymal) adipose tissue weight, serum levels of ALP, ALT, AST, and total and conjugated bilirubin, which were determined at the end of the study (after 7 weeks treatment). Microscopic histology of liver samples with hematoxylin and eosin staining (magnification: ×100 and ×200) was also performed.

# **Statistical Analysis**

Data were analyzed as mean  $\pm$  SD using GraphPad Prism version 6. ANOVA with Tukey-Kramer post-test was used to compare the means of different groups. P < 0.05 was considered significant.

# RESULTS

The qualitative phytochemical analysis revealed the presence of saponins, flavonoids, tannins, phytosterols, and cardiac glycosides, but absence of alkaloids and anthraquinones [Table 1].

# Effect of the Aqueous Leaf Extract of PP on Serum Levels of Liver Enzymes, Total and Conjugated Bilirubin, and Relative Liver Weights

Reduction in serum levels of ALP and AST was significant in the PP extract-treated group [Table 2]. No significant difference in the serum levels of alanine transaminase (ALT), and total and conjugated bilirubin [Table 2].

# Effect of the Aqueous Leaf Extract of PP on Weight Gain, White Adipose Tissue Mass, and Liver weight

The HFD-fed control group of animals exhibited a significant increase in weight gain and white adipose tissue mass compared to the negative control group on normal diet

Table 1: Phytochemical constituents of the aqueous leaf   extract of Phyllanthus pentandrus			
Phytochemical	Result of qualitative phytochemical analysis		
Alkaloids	Negative		
Cardiac glycosides	Positive		
Saponins	Positive		
Phytosterols	Positive		
Anthraquinones	Negative		
Flavonoids	Positive		
Tannins	Positive		

[Table 3]. On the other hand, compared to the HFD-fed group, a significant reduction in white adipose tissue mass, but not in weight gain, was observed in the group treated with the conventional drug Orlistat [Table 3]. Treatment with the PP extract (at 500 mg/kg) resulted in a significant reduction in the body weight gain and the adipose tissue mass when compared with the HFD-treated control group. However, no significant difference in the relative liver weights at autopsy was observed between the six groups [Table 3].

# Histological Examination of the Liver

HFD-fed group showed severe liver steatosis, which was ameliorated in the PP-treated group. The liver appeared normal in normal control and ORL-treated groups [Figures 1a-d].

# DISCUSSION

The use of HFD is currently the most common strategy of inducing NAFLD in rats.<sup>[14]</sup> The standard chow used to induce NAFLD in this study contains 7% fat and 15% protein. By adding moderate amount of sheep fat (40 g/100 g diet and whole milk powder (20 g/100 g diet), the resultant HFD contains about 11% protein (since the whole milk contains 27% protein), a level, though low that will not lead to deleterious effects.<sup>[15,16]</sup> The added sheep tallow (derived from perirenal fat by low-temperature cooking) consists, predominantly, of saturated fat, which is more likely to induce lipid accumulation in the liver, weight gain, and insulin resistance in rodents than unsaturated fat.<sup>[17]</sup> The animals fed with a HFD developed fatty liver disease (evidenced by macrovesicular and microvesicular liver steatosis) as well as a significant increase in weight gain and white adipose tissue mass. The elevation in the level of


**Table 2:** Effect of the aqueous leaf extract of *Phyllanthus pentandrus* on liver enzymes (ALP, AST, and ALT) and bilirubin (total and conjugated)

bilifubin (total and conjugated)						
<b>Treatment groups</b>	ALP (U/l)	AST (U/l)	ALT (U/l)	Total bilirubin (mg/dl)	Conjugated bilirubin (mg/dl)	
Normal control	41.91±12.93 <sup>b</sup>	101.22±32.20ª	25.06±4.34ª	0.31±0.18ª	0.13±0.06ª	
HFD control	102.54±18.42ª	107.54±14.91ª	30.22±11.75ª	$0.26{\pm}0.15^{a}$	$0.10{\pm}0.07^{a}$	
ORL+HFD	99.32±54.41ª	115.52±14.23ª	25.43±4.50ª	0.33±0.26ª	$0.14{\pm}0.08^{a}$	
PP+HFD	46.12±2.90 <sup>b</sup>	47.40±14.71 <sup>b</sup>	27.01±4.22ª	0.43±0.07ª	0.21±0.06ª	

Values are the mean $\pm$ standard deviation (*n*=6). Means with different lower case superscripts in the same column are significantly different at *P*<0.05. HFD: High-fat diet, ORL: Orlistat, PP: *Phyllanthus pentandrus* 

Table 3: Effect of the aqueous leaf extract of <i>Phyllanthus pentandrus</i> on weight gain, adipose tissue weight, and liver weight				
Treatment groups	Weight gain at week 7	White adipose tissue weight (g/100 g body weight)	Liver weight (g/100g body weight)	
Normal control	30.86±8.64 <sup>b</sup>	1.11±0.30°	3.02±0.24ª	
HFD control	70.50±13.12ª	5.04±1.22ª	3.73±1.01ª	
ORL+HFD	53.50±9.83ª	2.12±0.61 <sup>bc</sup>	2.72±0.44ª	
PP+HFD	17.88±10.40 <sup>b</sup>	3.10±0.83 <sup>b</sup>	3.31±0.80ª	

Values are the mean $\pm$ standard deviation (*n*=6). Means with different lower case superscripts in the same column are significantly different at *P*<0.05. HFD: High-fat diet, ORL: Orlistat, PP: *Phyllanthus pentandrus* 



**Figure 1:** Effect of aqueous leaf extract of *Phyllanthus pentandrus* and orlistat on high-fat diet (HFD)-induced liver steatosis after 7 weeks of treatment. Hematoxylin and eosin staining for microscopic histopathology of liver (magnification: ×100 and ×200) showing portal triad composed of portal vein, hepatic artery, and biliary duct surrounded by normal hepatocytes for normal rats administered with vehicle (a and b) and rats administered with HFD + orlistat (g and h) Rats administered with HFD + vehicle for 7 weeks showed severe steatosis (c and d), which was ameliorated by treatment with the PP extract (e and f)

the enzyme ALP (present in bile canaliculi) is indicative of obstructive liver disease. However, this study did not find any significant elevation in serum levels of other liver enzymes commonly tested for evaluation of liver, namely AST and ALT. Both orlistat and the PP extract ameliorated the observed fatty infiltration in the liver and the increase in adipose tissue mass. The PP extract, but not orlistat, reduced the observed body weight gain and brought back to normal the elevated ALP enzyme. Furthermore, contrary to orlistat, administration of the PP extract was beneficial in reducing the level of AST enzyme. Elevation in the serum level of this enzyme (found in hepatocellular cytosol) suggests liver disease; hence, reducing its level is a desirable pharmacological effect. The current study revealed that the aqueous leaf extract of PP possesses some phytochemical constituents such as tannins, cardiac glycosides, saponins, flavonoids, and phytosterols, but lacks alkaloids and anthraquinones.

The normal levels of ALT and AST in the HFD-fed rats as observed in this study agree with previous findings using a similar rat model of non-alcoholic steatohepatitis.<sup>[18]</sup> This is not surprising, since even in humans, up to 79% of patients with non-alcoholic steatohepatitis have normal serum levels of aminotransferase enzymes<sup>[19,20]</sup> and some patients with hepatic fibrosis as a sequela of steatohepatitis may present with a normal level of ALT.<sup>[21]</sup> Furthermore, an isolated elevation of ALP has been documented in some patients with NAFLD.<sup>[22]</sup> The observed potential beneficial effect of PP extract agrees with the findings that some members of the genus Phyllanthus ameliorated the features of NAFLD.<sup>[9,10]</sup> In addition, the body weight lowering effect of the extract is consistent with findings of previous studies which reported antiobesity activity of some species in the genus.<sup>[8]</sup> These properties may be, at least partly, attributed to the documented antioxidant and anti-inflammatory activities of some members of the genus Phyllanthus.[23-25] The observed beneficial effect of orlistat in reducing hepatic steatosis has been documented.<sup>[26]</sup> The drug is an inhibitor of pancreatic and gastric lipases, leading to reduction in the absorption of dietary fats.<sup>[27]</sup> The lack of beneficial effect of the standard drug orlistat in reducing the levels of liver enzymes, as found in this study, has previously been documented.<sup>[28]</sup> This indicates the superiority of PP extract over the standard drug in this respect. Some of the phytochemicals identified in the extract have been documented to possess hepatoprotective<sup>[29-32]</sup> and antiobesity properties [33-35] and any of them, alone or in combination, could, therefore, be contributory to such activities observed in the extract.

# Strength and Limitations of the Study

The current study is the first to report the potential beneficial effect of PP in reducing hepatic steatosis and causing weight loss in an animal model of NAFLD. The study has several limitations. Firstly, the constituents of the extract have not been precisely characterized using high-performance liquid chromatography and mass spectrometry. However, we have qualitatively identified certain phytoconstituents that have been found to exhibit hepatoprotective and antiobesity properties. In addition, we only investigated the effect of the PP extract at a single dose of 500 mg/kg/day (chosen based on a preliminary study showing it to be well tolerated by the rats).

# CONCLUSION

Aqueous extract of PP possesses hepatoprotective as well as body weight lowering effects; thus, it may be potentially useful in managing NAFLD.

#### ACKNOWLEDGMENTS

The authors are grateful to the laboratory staff of the Department of Pharmacology and Therapeutics, Usmanu Danfodiyo University, Sokoto, for their technical help during the conduct of the study.

# REFERENCES

- 1. Engin A. Non-alcoholic fatty liver disease. Adv Exp Med Biol 2017;960:443-67.
- Marchesini G, Moscatiello S, Di Domizio S, Forlani G. Obesity-associated liver disease. J Clin Endocrinol Metab 2008;93:S74-80.
- Lieber CS, Leo MA, Mak KM, Al E. Amodel of non-alcoholic fatty liver disease (NAFLD), including steatohepatitis (NASH), in rats fed a high fat Lieber-DeCarli diet. Hepatology 2002;36:402A.
- 4. Paschos P, Paletas K. Non alcoholic fatty liver disease two-hit process: Multifactorial character of the second hit. Hippokratia 2009;13:128.
- 5. Vernon G, Baranova A, Younossi ZM. Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34:274-85.
- Patel JR, Tripathi P, Sharma V, Chauhan NS, Dixit VK. Phyllanthus amarus: Ethnomedicinal uses, phytochemistry and pharmacology: A review. J Ethnopharmacol 2011;138:286-313.
- Adeneye AA, Amole OO, Adeneye AK. Hypoglycemic and hypocholesterolemic activities of the aqueous leaf and seed extract of phyllanthus amarus in mice. Fitoterapia 2006;77:511-4.
- 8. Ahmed AH. The effect of water extracts of *Phyllanthus emblica* and *Costus speciousus* on reducing obesity in albino rats. Alexandria Sci Exch J 2017;38:463-73.
- Al Zarzour RH, Ahmad M, Asmawi MZ, Kaur G, Saeed MAA, Al-Mansoub MA, *et al. Phyllanthus niruri* standardized extract alleviates the progression of non-alcoholic fatty liver disease and decreases atherosclerotic risk in sprague-dawley rats. Nutrients 2017;9:E766.
- 10. Huang CZ, Tung YT, Hsia SM, Wu CH, Yen GC. The hepatoprotective effect of *Phyllanthus emblica* L. Fruit on high fat diet-induced non-alcoholic fatty liver disease (NAFLD) in SD rats. Food Funct 2017;8:842-50.
- 11. Shen B, Yu J, Wang S, Chu ES, Wong VW, Zhou X, *et al. PHYLLANTHUS urinaria* ameliorates the severity of nutritional steatohepatitis both *in vitro* and *in vivo*. Hepatology 2008;47:473-83.
- 12. Yang Y, Zhou L, Gu Y, Zhang Y, Tang J, Li F, *et al.* Dietary chickpeas reverse visceral adiposity, dyslipidaemia and insulin resistance in rats induced by a chronic high-fat diet. Br J Nutr 2007;98:720-6.
- El-Olemy M, Al-Muhtadi F, Afifi A. Experimental Phytochemistry: A laboratory manual. Jedda: Department of Pharmacognosy, College of Pharmacy, King Saud University; 1994.
- Kucera O, Cervinkova Z. Experimental models of nonalcoholic fatty liver disease in rats. World J Gastroenterol 2014;20:8364-76.
- 15. Balakrishnan G, Ramachandran M, Banerjee BD, Hussain QZ. Effect of dietary protein, dichlorodiphenyltrichloroethane

(DDT) and hexachlorocyclohexane (HCH) on hepatic microsomal enzyme activity in rats. Br J Nutr 1985;54:563-6.

- 16. Matsuda S, Iwata K, Takahashi K, Homma H, Tamura Y, Kanda Y, *et al.* A low-protein diet concomitant with high calorie intake preserves renal function and structure in diabetic OLETF rats. Clin Exp Nephrol 2004;8:322-30.
- Buettner R, Parhofer KG, Woenckhaus M, Wrede CE, Kunz-Schughart LA, Schölmerich J, *et al.* Defining high-fat-diet rat models: Metabolic and molecular effects of different fat types. J Mol Endocrinol 2006;36:485-501.
- 18. Lieber CS, Leo MA, Mak KM, Xu Y, Cao Q, Ren C, *et al.* Model of nonalcoholic steatohepatitis. Am J Clin Nutr 2004;79:502-9.
- 19. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, *et al.* Prevalence of hepatic steatosis in an urban population in the united states: Impact of ethnicity. Hepatology 2004;40:1387-95.
- 20. Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 2008;134:1682-98.
- 21. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, *et al.* Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286-92.
- 22. Pantsari MW, Harrison SA. Nonalcoholic fatty liver disease presenting with an isolated elevated alkaline phosphatase. J Clin Gastroenterol 2006;40:633-5.
- 23. Kumaran A, Joel KR. *In vitro* antioxidant activities of methanol extracts of five *Phyllanthus* species from India. LWT-Food Sci Technol 2007;40:344-52.
- 24. Chularojmontri L, Wattanapitayakul SK, Herunsalee A, Charuchongkolwongse S, Niumsakul S, Srichairat S, *et al.* Antioxidative and cardioprotective effects of *Phyllanthus urinaria* L. On doxorubicin-induced cardiotoxicity. Biol Pharm Bull 2005;28:1165-71.
- 25. Rao YK, Fang SH, Tzeng YM. Anti-inflammatory activities of constituents isolated from phyllanthus polyphyllus. J Ethnopharmacol 2006;103:181-6.
- 26. Thamer SJ. The effect of orlistat and metformin treatment on body weight, liver steatsis, leptin and insulin sensitivity in obese rats fed high fat diet. J Am Sci 2014;10:107-14.
- 27. Wang H, Wang L, Cheng Y, Xia Z, Liao Y, Cao J, *et al.* Efficacy of orlistat in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Biomed Rep 2018;9:90-6.
- 28. Hala EM, Farida AA, Nagib RM. Beneficial effects of some beverage consumption and orlist drug on diet induced obesity in experimental rats. Life Sci J 2011;8:667-75.
- 29. Dong J, Peng X, Lu S, Zhou L, Qiu M. Hepatoprotective steroids from roots of *Cynanchum otophyllum*. Fitoterapia 2019;136:104171.
- 30. Huang Q, Zhang S, Zheng L, He M, Huang R, Lin X, *et al.* Hepatoprotective effects of total saponins isolated from taraphochlamys affinis against carbon tetrachloride induced liver injury in rats. Food Chem Toxicol 2012;50:713-8.
- 31. Jayaraj R, Deb U, Bhaskar AS, Prasad GB, Rao PV. Hepatoprotective efficacy of certain flavonoids against microcystin induced toxicity in mice. Environ Toxicol 2007;22:472-9.
- 32. Shimoda H, Tanaka J, Kikuchi M, Fukuda T, Ito H, Hatano T, *et al.* Walnut polyphenols prevent liver damage induced by carbon tetrachloride and d-galactosamine: Hepatoprotective hydrolyzable tannins in the kernel pellicles of walnut. J Agric Food Chem 2008;56:4444-9.

- Kawser Hossain M, Abdal Dayem A, Han J, Yin Y, Kim K, Kumar Saha S, *et al.* Molecular mechanisms of the anti-obesity and antidiabetic properties of flavonoids. Int J Mol Sci 2016;17:569.
- Hu X, Li Z, Xue Y, Xu J, Xue C, Wang J, *et al.* Dietary saponins of sea cucumber ameliorate obesity, hepatic steatosis, and glucose intolerance in high-fat diet-fed mice. J Med Food 2012;15:909-16.
- 35. Schwartz AG, Lewbart ML. Research Corp Technologies Inc, Assignee. Steroids Useful as Anti-cancer and Anti-obesity Agents. United States Patent US; 1998.

**How to cite this article:** Chikaa A, Bello SO. Hepatoprotective and body weight lowering effects of the aqueous leaf extract of *Phyllanthus pentandrus* Schumach. and Thonn (*Phyllanthaceae*) in nonalcoholic fatty liver disease induced by a high-fat diet in Wistar rats. Natl J Physiol Pharm Pharmacol 2019;9(12):1251-1256.

Source of Support: Nil, Conflict of Interest: None declared.